Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50745 |
Name | diffuse large B-cell lymphoma |
Definition | A large B-cell lymphoma that is consisting of medium-sized to large B cells with a diffuse growth pattern. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma diffuse large B-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | Idelalisib + MK2206 | diffuse large B-cell lymphoma | predicted - sensitive | detail... |
PTEN loss | GSK2334470 + Idelalisib | diffuse large B-cell lymphoma | predicted - sensitive | detail... |
BRAF V600E | ERAS-007 | diffuse large B-cell lymphoma | sensitive | detail... |
ALK I1171N ALK pos | Lorlatinib | diffuse large B-cell lymphoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00001337 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT00006436 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00918463 | Phase II | Dasatinib | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT00978432 | Phase II | Everolimus + Panobinostat | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Completed | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01334502 | Phase I | Everolimus Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01431209 | Phase II | Ruxolitinib | Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01449461 | Phase Ib/II | Brigatinib | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Completed | 0 | |
NCT01453205 | Phase II | Cisplatin + Cytarabine + Dexamethasone Carboplatin + Etoposide + Ifosfamide Rituximab MEDI-551 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | TUR | POL | ISR | HUN | FRA | ESP | DEU | CZE | CAN | 1 |
NCT01686165 | Phase II | Belinostat Rituximab | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01691898 | Phase Ib/II | Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) | Completed | USA | NLD | ITA | FRA | DEU | CAN | 0 |
NCT01719250 | Phase I | Buparlisib | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01742988 | Phase Ib/II | Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Completed | USA | 0 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01854606 | Phase Ib/II | Everolimus + Sotrastaurin | Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma | Completed | USA | NLD | ITA | FRA | DEU | 3 |
NCT01855750 | Phase III | Ibrutinib Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | Completed | USA | TUR | SWE | POL | NOR | NLD | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 7 |
NCT01859819 | Phase II | Cytarabine + Rituximab | Treatment for Advanced B-Cell Lymphoma | Completed | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01938638 | Phase I | BAY1143572 | Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | Completed | USA | 3 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01955499 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT01959698 | Phase Ib/II | Carfilzomib + Rituximab Carboplatin + Etoposide + Ifosfamide | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT01992653 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | Completed | USA | FRA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02029443 | Phase Ib/II | Acalabrutinib | ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ITA | GBR | 0 |
NCT02031419 | Phase I | CC-122 + Spebrutinib Onatasertib + Spebrutinib CC-122 + Onatasertib Rituximab | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma | Terminated | USA | ITA | FRA | CAN | 0 |
NCT02055820 | Phase I | Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Obinutuzumab | A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma | Completed | USA | NLD | ITA | HUN | FRA | ESP | CZE | CAN | AUT | AUS | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02073097 | Phase Ib/II | Carfilzomib + Rituximab Cyclophosphamide + Doxorubicin + Vincristine Sulfate | Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT02077166 | Phase Ib/II | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | USA | GBR | DEU | BEL | 0 |
NCT02082977 | Phase I | GSK126 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma | Terminated | USA | GBR | FRA | 0 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | POL | DEU | CZE | 0 |
NCT02138786 | Phase II | Selinexor | Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT) | Terminated | USA | POL | GBR | ESP | DEU | 0 |
NCT02141451 | Phase Ib/II | INCB7839 + Rituximab | ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL | Completed | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02181218 | Phase I | Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | Completed | USA | 0 |
NCT02203526 | Phase I | Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal doxorubicin + Temozolomide Cytarabine Rituximab | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma | Recruiting | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02219737 | Phase I | Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab | Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Completed | USA | 0 |
NCT02220842 | Phase I | Atezolizumab + Obinutuzumab | A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | Completed | USA | ITA | GBR | FRA | DEU | 0 |
NCT02226965 | Phase II | PNT2258 | Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL | Completed | USA | 1 |
NCT02227251 | Phase II | Selinexor | Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL) | Recruiting | USA | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BGR | BEL | AUT | AUS | 2 |
NCT02229981 | Phase Ib/II | ABC294640 | An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma | Withdrawn | USA | 0 |
NCT02252146 | Phase Ib/II | Bazlitoran | Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation | Completed | USA | 0 |
NCT02257567 | Phase Ib/II | Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | Completed | USA | TUR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 1 |
NCT02282358 | Phase Ib/II | Mocetinostat | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Terminated | USA | 0 |
NCT02303392 | Phase I | Ibrutinib + Selinexor | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT02315326 | Phase Ib/II | Ibrutinib | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | Recruiting | USA | 0 |
NCT02323230 | Phase II | Cyclophosphamide + Maveropepimut-S | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | Terminated | CAN | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02343536 | Phase I | Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Azacitidine | A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma | Completed | USA | 0 |
NCT02348216 | Phase Ib/II | axicabtagene ciloleucel | A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | Completed | USA | NLD | ISR | FRA | DEU | CAN | 0 |
NCT02361346 | Phase Ib/II | MT-3724 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) | Terminated | USA | POL | ISR | ESP | CAN | 5 |
NCT02362997 | Phase II | Pembrolizumab | Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL | Completed | USA | 0 |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |
NCT02391116 | Phase II | Copanlisib | Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Completed | ITA | GBR | FRA | DNK | DEU | CAN | BEL | AUS | 2 |
NCT02393157 | Phase II | Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) | Recruiting | USA | 0 |
NCT02399085 | Phase II | Lenalidomide + Tafasitamab-cxix | A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BEL | 0 |
NCT02401048 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | Completed | USA | 0 |
NCT02408042 | Phase Ib/II | Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Withdrawn | USA | 0 |
NCT02420795 | Phase Ib/II | ONC201 | Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT02436707 | Phase II | Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02443077 | Phase III | Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Active, not recruiting | USA | 1 |
NCT02445248 | Phase II | Tisagenlecleucel | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET) | Completed | USA | NOR | NLD | ITA | FRA | DEU | CAN | AUT | AUS | 1 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | ISR | FRA | ESP | BEL | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02471911 | Phase I | Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Completed | USA | 0 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02530125 | Phase II | Pidilizumab | Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission | Terminated | USA | 0 |
NCT02531308 | Phase II | Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Pegfilgrastim Rituximab | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
NCT02541565 | Phase I | Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Rituximab | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma | Completed | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02549651 | Phase I | Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) | Completed | USA | IRL | GBR | FRA | 0 |
NCT02564744 | Phase II | Naratuximab emtansine + Rituximab | Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL | Completed | USA | POL | ITA | HUN | CZE | CHE | BGR | BEL | 1 |
NCT02570542 | Phase II | Plerixafor Carmustine + Cytarabine + Etoposide + Melphalan | Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Active, not recruiting | USA | 0 |
NCT02572453 | Phase II | Onalespib | Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT02576990 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) | Completed | 0 | |
NCT02580552 | Phase I | MRG-106 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Completed | USA | 0 |
NCT02581631 | Phase Ib/II | Brentuximab vedotin + Nivolumab | A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) | Completed | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT02589145 | Phase Ib/II | Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | Terminated | USA | 0 |
NCT02596971 | Phase Ib/II | Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | GBR | ESP | 0 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02624986 | Phase Ib/II | Idasanutlin + Obinutuzumab | A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | NZL | DEU | AUS | 1 |
NCT02628405 | Phase Ib/II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Completed | USA | 0 |
NCT02636322 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Ibrutinib + Lenalidomide + Rituximab Prednisone | A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT02650999 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas | Completed | USA | 0 |
NCT02658968 | Phase I | Betalutin | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | Completed | USA | ITA | GBR | ESP | DEU | 0 |
NCT02674750 | Phase II | CUDC-907 | Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations | Completed | USA | ESP | 0 |
NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Terminated | USA | 0 |
NCT02684617 | Phase I | Dinaciclib + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) | Terminated | 0 | |
NCT02698189 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) | Terminated | 0 | |
NCT02700022 | Phase I | Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | Terminated | USA | 0 |
NCT02701673 | Phase Ib/II | Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | Withdrawn | 0 | |
NCT02706405 | Phase I | Cyclophosphamide + Durvalumab + JCAR014 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02729896 | Phase Ib/II | Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | POL | DEU | 0 |
NCT02734771 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | USA | 0 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02756247 | Phase I | Buparlisib + Ibrutinib | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Completed | USA | 0 |
NCT02760485 | Phase Ib/II | Ibrutinib + Itacitinib | A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT02763254 | Phase II | CMD-003 | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) | Terminated | USA | 0 |
NCT02763319 | Phase II | Bendamustine + Tafasitamab-cxix Bendamustine + Rituximab | A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) | Completed | USA | TUR | ROU | POL | NZL | ITA | ISR | HUN | HRV | GBR | FRA | FIN | ESP | DEU | CZE | CAN | AUT | AUS | 5 |
NCT02776813 | Phase I | ACTR087 + Rituximab | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Completed | USA | 0 |
NCT02793583 | Phase II | Umbralisib Ublituximab + Umbralisib | Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL) | Terminated | USA | SVK | POL | ITA | ISR | GBR | ESP | AUS | 1 |
NCT02815397 | Phase II | Metformin | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma | Terminated | USA | 0 |
NCT02874404 | Phase II | Ibrutinib + Umbralisib | TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT02889523 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Tazemetostat + Vincristine Sulfate | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP) | Active, not recruiting | FRA | BEL | 0 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT02909777 | Phase I | CUDC-907 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | Active, not recruiting | USA | 0 |
NCT02914938 | Phase I | zandelisib Rituximab + zandelisib | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Terminated | USA | CHE | 0 |
NCT02926833 | Phase Ib/II | Atezolizumab + axicabtagene ciloleucel | A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) | Completed | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02951156 | Phase III | Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Terminated | USA | POL | ITA | GBR | ESP | BEL | AUS | 1 |
NCT02953509 | Phase Ib/II | Hu5F9-G4 + Rituximab | Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Terminated | USA | GBR | AUS | 0 |
NCT02961816 | Phase II | Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | Withdrawn | 0 | |
NCT02998476 | Phase II | Parsaclisib | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | Completed | USA | POL | ITA | GBR | FRA | ESP | CZE | CAN | BEL | AUS | 1 |
NCT03003520 | Phase II | Cyclophosphamide + Doxorubicin + Durvalumab + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Durvalumab + Prednisone + Rituximab + Vincristine Sulfate | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | Completed | USA | GBR | EST | DNK | AUT | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT03028103 | Phase I | Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects | Completed | USA | 0 |
NCT03036904 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) | Completed | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03064867 | Phase I | Carboplatin + Etoposide + Ifosfamide + Rituximab + Venetoclax | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03103971 | Phase I | Cyclophosphamide + Fludarabine + HuJCAR014 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT03106428 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | Completed | USA | FRA | 1 |
NCT03123393 | Phase II | Mivavotinib | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT03129828 | Phase Ib/II | Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) | Active, not recruiting | DEU | 0 |
NCT03135262 | Phase Ib/II | Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | NZL | DEU | AUS | 1 |
NCT03136497 | Phase I | Ibrutinib + Rituximab + Venetoclax | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03150329 | Phase I | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03153462 | Expanded access | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03189836 | Phase I | ACTR707 + Rituximab | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Terminated | USA | 0 |
NCT03205046 | Phase Ib/II | Acalabrutinib + Vistusertib | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | Terminated | USA | GBR | 0 |
NCT03206671 | Phase III | Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Vincristine Sulfate | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013) | Recruiting | SWE | NOR | FIN | DNK | DEU | CZE | CHE | AUT | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03220022 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Ibrutinib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | Recruiting | USA | 0 |
NCT03220347 | Phase I | CC-90010 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas | Terminated | ITA | FRA | ESP | 1 |
NCT03244176 | Phase I | Avelumab | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP) | Active, not recruiting | AUS | 0 |
NCT03255018 | Phase II | Pembrolizumab | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas | Completed | USA | 0 |
NCT03255096 | Phase I | Rituximab + TEN-010 + Venetoclax | A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ESP | DNK | AUS | 0 |
NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03263026 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Enzastaurin | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 | Completed | USA | 1 |
NCT03274492 | Phase III | Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX) | Active, not recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT03277729 | Phase Ib/II | CD20 CAR-T cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03283202 | Phase I | CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors | Completed | USA | ESP | CAN | BEL | 0 |
NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Completed | USA | GBR | 0 |
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Completed | USA | 0 |
NCT03305445 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | Completed | USA | 0 |
NCT03309878 | Phase Ib/II | Pembrolizumab Mogamulizumab + Pembrolizumab | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas | Completed | USA | 0 |
NCT03311958 | Phase I | Nivolumab | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | Active, not recruiting | USA | 0 |
NCT03316573 | Phase II | Pembrolizumab | A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas | Suspended | USA | 0 |
NCT03321643 | Phase I | Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab | Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03349450 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab Maveropepimut-S | DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) | Completed | CAN | 0 |
NCT03352765 | Phase I | Bendamustine + Melphalan + Rituximab | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | Active, not recruiting | USA | 0 |
NCT03356054 | Phase Ib/II | Brentuximab vedotin + Cisplatin + Cytarabine + Dexamethasone + Rituximab | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL) | Recruiting | NLD | 0 |
NCT03357627 | Phase I | Mivavotinib + Venetoclax | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Completed | USA | DEU | CAN | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03391466 | Phase III | axicabtagene ciloleucel | A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 0 |
NCT03399513 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ibrutinib + Prednisolone + Rituximab + Vincristine Sulfate | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut) | Completed | DEU | 0 |
NCT03418038 | Phase II | Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma | Recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03424122 | Phase I | Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | Completed | USA | ITA | ESP | 0 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03440567 | Phase I | Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | POL | ESP | BGR | 4 |
NCT03467373 | Phase I | Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03483103 | Phase II | Lisocabtagene maraleucel | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Completed | USA | 0 |
NCT03484702 | Phase II | Lisocabtagene maraleucel | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) | Completed | NLD | ITA | GBR | FRA | FIN | ESP | DEU | CHE | BEL | AUT | 1 |
NCT03484819 | Phase II | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03488251 | Phase II | Gemcitabine + MT-3724 + Oxaliplatin | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT03495960 | Phase II | Rituximab + Temozolomide Lenalidomide + Methotrexate + Procarbazine + Rituximab | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA) | Recruiting | ITA | ISR | FIN | DNK | CHE | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03543813 | Phase Ib/II | CX-2029 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Completed | USA | GBR | ESP | 1 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03558750 | Phase Ib/II | Lenalidomide + Nivolumab + Rituximab | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | Terminated | USA | 0 |
NCT03571828 | Phase I | AMG562 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Terminated | USA | DEU | CAN | BEL | 0 |
NCT03586024 | Phase Ib/II | Pembrolizumab | Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) | Withdrawn | USA | 0 |
NCT03589469 | Phase II | Loncastuximab tesirine-lpyl | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | USA | ITA | GBR | CHE | 0 |
NCT03598608 | Phase Ib/II | MK-4280 + Pembrolizumab | Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | Recruiting | USA | ITA | ISR | DEU | CAN | AUS | 0 |
NCT03610061 | Phase I | Durvalumab | A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD) | Completed | AUS | 0 |
NCT03610724 | Phase II | Tisagenlecleucel | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) | Completed | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03630159 | Phase I | Pembrolizumab + Tisagenlecleucel | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) | Completed | USA | CAN | AUT | 0 |
NCT03645395 | Phase II | Lenalidomide + MT-3724 | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) | Terminated | USA | 0 |
NCT03671018 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Tocilizumab | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | GBR | ESP | CAN | BEL | 0 |
NCT03677141 | Phase Ib/II | Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | Completed | USA | POL | FRA | ESP | AUT | 1 |
NCT03677154 | Phase Ib/II | Mosunetuzumab-axgb + Tocilizumab | A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy | Active, not recruiting | USA | POL | ISR | ESP | 2 |
NCT03682796 | Phase I | TRPH-222 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Completed | USA | CAN | 0 |
NCT03685344 | Phase I | Durvalumab + Loncastuximab tesirine-lpyl | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | Terminated | USA | ESP | 0 |
NCT03688451 | Phase II | Rituximab | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03703167 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | Active, not recruiting | USA | 0 |
NCT03704714 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | Suspended | USA | 0 |
NCT03731234 | Phase II | Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance | Recruiting | ITA | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03742258 | Phase I | Cyclophosphamide + Doxorubicin + Mivavotinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | Unknown status | USA | 0 |
NCT03743246 | Phase Ib/II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | Terminated | USA | NLD | ITA | FRA | ESP | DEU | 0 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | USA | 0 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03758989 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03797261 | Phase I | AMG 176 + Venetoclax | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | DEU | AUS | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03843294 | Phase I | MultiTAA-specific T cells + Nivolumab | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | Active, not recruiting | USA | 0 |
NCT03876028 | Phase I | Ibrutinib + Tisagenlecleucel | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | Terminated | USA | 0 |
NCT03884998 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Completed | USA | 0 |
NCT03892044 | Phase I | Duvelisib + Nivolumab | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | Completed | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03939026 | Phase I | UCART19 ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) | Active, not recruiting | USA | 0 |
NCT03939182 | Phase Ib/II | Abexinostat + Ibrutinib | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03943901 | Phase II | Cyclophosphamide + Doxorubicin + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate | Split-Dose R-CHOP for Older Adults With DLBCL | Active, not recruiting | USA | 0 |
NCT03955783 | Phase I | Selinexor + Venetoclax | Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies | Completed | USA | 0 |
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT03984448 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT03990961 | Phase II | Pembrolizumab | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Completed | USA | 0 |
NCT03995147 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Sulfate | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04002401 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine + Rituximab | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | Completed | USA | 0 |
NCT04002947 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04074330 | Phase Ib/II | Rituximab + Subasumstat | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT04082936 | Phase I | IGM-2323 | A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | CZE | AUS | 1 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04094311 | Phase III | Tisagenlecleucel | Study of Out of Specification for Tisagenlecleucel | Recruiting | CAN | 1 |
NCT04113226 | Phase II | Rituximab Lenalidomide + Rituximab | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage) | Recruiting | FRA | 0 |
NCT04134936 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | Completed | USA | ITA | FRA | ESP | DEU | CZE | BEL | AUT | 1 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04139304 | Phase I | Cyclophosphamide + Daratumumab + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Active, not recruiting | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04161118 | Phase II | huCART19 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) | Terminated | DEU | 0 |
NCT04161248 | Phase I | Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT04182204 | Phase III | Gemcitabine + Oxaliplatin + Rituximab Gemcitabine + Oxaliplatin + Polatuzumab vedotin-piiq + Rituximab | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | TUR | ITA | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BRA | 4 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04205838 | Phase II | Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Completed | USA | CAN | 0 |
NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04257578 | Phase Ib/II | Acalabrutinib + axicabtagene ciloleucel | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | USA | 0 |
NCT04263584 | Phase II | Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) | Active, not recruiting | DEU | 0 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04305444 | Phase II | DTRMWXHS-12 + Everolimus + Pomalidomide | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Terminated | USA | 0 |
NCT04323956 | Phase I | Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate | Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04384484 | Phase III | Loncastuximab tesirine-lpyl + Rituximab Gemcitabine + Oxaliplatin + Rituximab | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | CZE | CHE | CAN | BRA | BEL | ARG | 5 |
NCT04390737 | Phase I | HH2853 | A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. | Recruiting | USA | 1 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04404283 | Phase III | Lenalidomide + Rituximab Brentuximab vedotin + Lenalidomide + Rituximab | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUS | 2 |
NCT04408638 | Phase III | Obinutuzumab Gemcitabine + Oxaliplatin + Rituximab Gemcitabine + Glofitamab-gxbm + Oxaliplatin | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | POL | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUS | 4 |
NCT04419909 | Phase I | huCART19 | Retreatment With CTL019/CTL119 | Not yet recruiting | USA | 0 |
NCT04433182 | Phase II | Bendamustine + Copanlisib + Rituximab Copanlisib | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | Active, not recruiting | ITA | 0 |
NCT04442022 | Phase II | Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | POL | ITA | ISR | ESP | AUT | 1 |
NCT04479267 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | Recruiting | USA | 0 |
NCT04491370 | Phase Ib/II | Polatuzumab vedotin-piiq | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04500587 | Phase I | ZN-d5 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | Completed | POL | HRV | ESP | BGR | AUS | 2 |
NCT04502446 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies | Active, not recruiting | USA | CAN | AUS | 0 |
NCT04502706 | Phase I | FSI-189 FSI-189 + Rituximab | Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04512716 | Phase I | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells + Iomab-B | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04517435 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate + zandelisib | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04529772 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE) | Active, not recruiting | USA | TUR | POL | ITA | ISR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 9 |
NCT04531046 | Phase II | axicabtagene ciloleucel | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | Active, not recruiting | FRA | BEL | 0 |
NCT04535102 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | POLA+BR for Relapsed or Refractory DLBCL | Withdrawn | 0 | |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04546620 | Phase II | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A) | Recruiting | GBR | 0 |
NCT04555811 | Phase I | FT596 + Rituximab | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | Completed | USA | 0 |
NCT04572763 | Phase Ib/II | Copanlisib + Venetoclax | Copanlisib Plus Venetoclax in R/R DLBCL | Active, not recruiting | USA | 0 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 3 |
NCT04594798 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | Recruiting | USA | 0 |
NCT04604067 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | Recruiting | ITA | CHE | 0 |
NCT04607772 | Phase Ib/II | Selinexor + Venetoclax Ibrutinib + Rituximab + Selinexor Lenalidomide + Rituximab + Selinexor Lenalidomide + Selinexor + Tafasitamab-cxix Bendamustine + Rituximab + Selinexor Polatuzumab vedotin-piiq + Rituximab + Selinexor Bendamustine + Polatuzumab vedotin-piiq + Rituximab + Selinexor Gemcitabine + Oxaliplatin + Rituximab + Selinexor | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | Suspended | USA | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Active, not recruiting | USA | 0 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 0 |
NCT04628494 | Phase III | Gemcitabine + Oxaliplatin + Rituximab Epcoritamab-bysp Bendamustine + Rituximab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BEL | AUT | AUS | 6 |
NCT04630756 | Phase Ib/II | Acalabrutinib + AZD4573 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer. | Active, not recruiting | USA | POL | IRL | GBR | FRA | ESP | CAN | AUS | 1 |
NCT04640779 | Phase I | Choline salicylate + Selinexor | Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04663347 | Phase Ib/II | Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2) | Recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | CZE | BEL | AUS | 0 |
NCT04665765 | Phase II | Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04676360 | Phase II | belantamab mafodotin-blmf | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04703686 | Phase II | Glofitamab-gxbm + Obinutuzumab | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Active, not recruiting | FRA | 0 |
NCT04739813 | Phase I | Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04790903 | Phase I | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Venetoclax | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | ITA | FRA | ESP | 0 |
NCT04799275 | Phase II | Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04824092 | Phase III | Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | AUS | ARG | 10 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04833114 | Phase III | Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) | Recruiting | GBR | ESP | DEU | AUT | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04844866 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) | Active, not recruiting | SWE | POL | NLD | LTU | ITA | HUN | FRA | ESP | DEU | CZE | BEL | AUT | 0 |
NCT04850495 | Phase I | Cyclophosphamide + Doxorubicin + Rituximab + Vincristine Sulfate + Zanubrutinib | Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04855253 | Phase Ib/II | E7777 | Study of E7777 Prior to Kymriah for R/R DLBCL | Recruiting | USA | 0 |
NCT04882163 | Phase Ib/II | Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | Withdrawn | USA | GBR | FRA | ESP | BEL | AUT | 2 |
NCT04889716 | Phase II | Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb | CAR-T Followed by Bispecific Antibodies | Recruiting | USA | 0 |
NCT04890236 | Phase I | Tisagenlecleucel Duvelisib | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | Recruiting | USA | 0 |
NCT04903197 | Phase I | Lenalidomide + VAY736 VAY736 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | Active, not recruiting | ITA | DEU | AUS | 4 |
NCT04906902 | Phase Ib/II | Acalabrutinib | Acalabrutinib in CNSL | Recruiting | USA | 0 |
NCT04914741 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisolone + Rituximab | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION) | Active, not recruiting | AUS | 0 |
NCT04920617 | Phase II | Maveropepimut-S Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | ROU | POL | NZL | HUN | FRA | ESP | CAN | AUS | 1 |
NCT04933617 | Phase I | Copanlisib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | Terminated | USA | 0 |
NCT04974216 | Phase II | Lenalidomide + Rituximab + Tafasitamab-cxix | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | Active, not recruiting | FRA | BEL | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04978584 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Acalabrutinib + Lenalidomide + Rituximab + Tafasitamab-cxix | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | Recruiting | USA | 0 |
NCT04980222 | Phase II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | POL | NLD | FRA | ESP | DNK | 0 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05011058 | Phase II | CHR-3996 CHR-3996 + Valganciclovir | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05052528 | Phase I | Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine + Rituximab | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05075603 | Phase I | Tisagenlecleucel | A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah) in Relapsed/Refractory Large B-cell Lymphoma Subjects | Recruiting | USA | 0 |
NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05098613 | Phase I | CD19/CD22 CAR T cells | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | Recruiting | USA | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05121103 | Phase I | EZM0414 | A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Terminated | USA | 0 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |
NCT05139017 | Phase II | Bendamustine + Rituximab + VLS-101 Gemcitabine + Oxaliplatin + Rituximab + VLS-101 Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | CAN | 4 |
NCT05144009 | Phase II | Loncastuximab tesirine-lpyl + Rituximab | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) | Completed | USA | ITA | ESP | 1 |
NCT05144841 | Phase II | VLS-101 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | FRA | EST | ESP | CZE | CAN | 4 |
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | NLD | ITA | GRC | ESP | 0 |
NCT05169515 | Phase I | Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | ITA | ISR | GBR | ESP | 0 |
NCT05171647 | Phase III | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) | Active, not recruiting | USA | TUR | NZL | ISR | CAN | BRA | ARG | 6 |
NCT05179603 | Phase II | THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) | Terminated | ESP | ARG | 1 |
NCT05202782 | Phase II | Zanubrutinib | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT05205161 | Phase Ib/II | AZD0466 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | AUS | 2 |
NCT05205252 | Phase Ib/II | Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) | Withdrawn | USA | 0 |
NCT05206357 | Phase I | Epcoritamab-bysp | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | Recruiting | USA | TUR | ITA | ISR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT05207670 | Phase II | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | Active, not recruiting | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Active, not recruiting | USA | 0 |
NCT05221645 | Phase II | Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Pembrolizumab + Rituximab | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE) | Recruiting | GBR | 0 |
NCT05222555 | Phase Ib/II | Lenalidomide + Tafasitamab-cxix | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway) | Active, not recruiting | USA | POL | ITA | ISR | FRA | ESP | CZE | AUT | 1 |
NCT05233033 | Phase I | KT-413 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL | Suspended | USA | GBR | 0 |
NCT05253495 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) | Recruiting | USA | 0 |
NCT05255601 | Phase Ib/II | Nivolumab + Relatlimab | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05260957 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Recruiting | USA | 0 |
NCT05270057 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) | Recruiting | USA | 0 |
NCT05272384 | Phase I | Decitabine and Cedazuridine + Nivolumab | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05275504 | Phase I | TT-01488 | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | Unknown status | USA | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05283720 | Phase II | Epcoritamab-bysp + Lenalidomide Epcoritamab-bysp + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Recruiting | USA | NLD | ISR | HUN | FRA | ESP | DNK | DEU | CZE | 3 |
NCT05296525 | Phase Ib/II | GDA-201 | Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | Terminated | USA | 0 |
NCT05315713 | Phase Ib/II | Mosunetuzumab-axgb + Tiragolumab + Tocilizumab Atezolizumab + Mosunetuzumab-axgb + Tiragolumab + Tocilizumab | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | Terminated | USA | GBR | DEU | CAN | BEL | AUS | 0 |
NCT05319028 | Phase II | Mivavotinib | Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT05328102 | Phase II | Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + XmAb13676 | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL | Terminated | USA | FRA | ESP | 0 |
NCT05338346 | Phase I | ATG-018 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) | Terminated | AUS | 0 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05359211 | Phase I | NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05406401 | Phase II | Prednisolone Prednisone Cyclophosphamide + Doxorubicin + Rituximab + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | Active, not recruiting | TUR | POL | ITA | ISR | ESP | CAN | 1 |
NCT05412290 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05429268 | Phase III | Lenalidomide + Tafasitamab-cxix | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Recruiting | TUR | ROU | POL | NOR | ISR | IRL | HUN | HRV | GBR | FIN | DNK | CZE | BGR | 1 |
NCT05442515 | Phase Ib/II | CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT05451810 | Phase II | Epcoritamab-bysp | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | Recruiting | USA | 1 |
NCT05453396 | Phase II | Loncastuximab tesirine-lpyl | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05455697 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate | Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05459571 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) | Active, not recruiting | USA | 0 |
NCT05464329 | Phase I | Mosunetuzumab-axgb | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | Recruiting | USA | 0 |
NCT05464719 | Phase II | Loncastuximab tesirine-lpyl | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | Recruiting | USA | 0 |
NCT05498220 | Phase II | Cisplatin + Dexamethasone + Gemcitabine + Hyaluronidase + Polatuzumab vedotin-piiq + Rituximab + Sargramostim | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05512390 | Phase I | ABBV-319 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | ISR | CAN | AUS | 0 |
NCT05533775 | Phase Ib/II | Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |
NCT05537766 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CHE | AUT | 0 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05578976 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) | Recruiting | USA | TUR | SWE | SVK | POL | NZL | NLD | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 7 |
NCT05583149 | Phase II | Acalabrutinib + Lisocabtagene maraleucel | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | Recruiting | USA | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05600686 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05605899 | Phase III | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | A Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 2 |
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |
NCT05615636 | Phase II | Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tafasitamab-cxix | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | Recruiting | USA | 0 |
NCT05618028 | Phase I | ABBV-525 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT05618366 | Phase I | Tazemetostat + Venetoclax | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05626322 | Phase II | Lenalidomide + Tafasitamab-cxix + TTI-622 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Active, not recruiting | USA | 3 |
NCT05633615 | Phase II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |
NCT05660395 | Phase I | Loncastuximab tesirine-lpyl | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | Recruiting | USA | BRA | 2 |
NCT05660967 | Phase II | Epcoritamab-bysp Epcoritamab-bysp + Lenalidomide | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUT | 2 |
NCT05664217 | Phase II | NKTR-255 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05714345 | Phase II | Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) | Active, not recruiting | USA | BEL | 0 |
NCT05737628 | Phase I | BYON4228 + Rituximab | First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228 | Recruiting | NLD | ITA | GBR | ESP | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05755087 | Phase I | BC2059 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05757219 | Phase II | axicabtagene ciloleucel + Itacitinib | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Recruiting | USA | 0 |
NCT05757700 | Phase I | 19(T2)28z1xx TRAC CAR-T cells | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05794958 | Phase I | axicabtagene ciloleucel | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | Recruiting | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05798897 | Phase I | MT-601 | Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) | Recruiting | USA | 0 |
NCT05800366 | Phase II | Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05801913 | Phase I | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05820841 | Phase III | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) | Recruiting | DEU | 0 |
NCT05821088 | Phase II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05826535 | Phase Ib/II | IMPT-314 | Study of IMPT-314 in R/R Aggressive B-cell | Recruiting | USA | 0 |
NCT05828589 | Phase I | BGB-21447 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Recruiting | AUS | 1 |
NCT05873712 | Phase II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |
NCT05890352 | Phase II | Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + Tazemetostat Lenalidomide + Tafasitamab-cxix + Zanubrutinib | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Recruiting | USA | 0 |
NCT05896163 | Phase Ib/II | Glofitamab-gxbm + Obinutuzumab + TTI-622 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. | Recruiting | USA | ISR | AUS | 2 |
NCT05908409 | Phase Ib/II | IDP-121 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | ESP | 0 |
NCT05929716 | Phase II | Hu5F9-G4 + Rituximab | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | Withdrawn | 0 | |
NCT05934448 | Phase II | Pembrolizumab | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | Recruiting | USA | 0 |
NCT05934838 | Phase I | Tazemetostat | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | Recruiting | USA | 0 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05950334 | Phase I | Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Recruiting | USA | 0 |
NCT05952024 | Phase II | Acalabrutinib + Rituximab | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) | Recruiting | USA | BRA | 2 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05972720 | Phase II | Cyclophosphamide + Fludarabine CRG-022 | A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT05991388 | Phase II | Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab tesirine-lpyl + Rituximab Odronextamab Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL) | Recruiting | GBR | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |
NCT06015880 | Phase I | Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06045247 | Phase II | Cyclophosphamide + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT06071871 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) | Recruiting | GBR | 0 |
NCT06079164 | Phase I | KITE-197 Cyclophosphamide + Fludarabine | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | CAN | AUS | 0 |
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
NCT06090539 | Phase I | BMS-986458 + Rituximab BMS-986458 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06091865 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Odronextamab + Prednisone + Vincristine Sulfate | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3) | Recruiting | USA | TUR | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS | 6 |
NCT06101381 | Phase Ib/II | huCART19 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) | Not yet recruiting | BRA | 0 |
NCT06132503 | Phase I | LP-284 | A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors | Recruiting | USA | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Not yet recruiting | CAN | 0 |
NCT06238648 | Phase II | Epcoritamab-bysp | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Recruiting | USA | 0 |
NCT06242834 | Phase II | Pembrolizumab + Tazemetostat | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |
NCT06249191 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT06254495 | Phase I | SGN-35C | A Safety Study of SGN-35C in Adults With Advanced Cancers | Recruiting | USA | ITA | DNK | 0 |
NCT06271057 | Phase II | CC-99282 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | Recruiting | FRA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06287398 | Phase II | Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Recruiting | AUS | 0 |
NCT06290622 | Phase I | INCAGN02385 + INCAGN02390 + Retifanlimab | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Withdrawn | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06356129 | Phase III | CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NZL | NOR | NLD | ITA | HUN | HRV | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 14 |
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06395103 | Phase Ib/II | VLS-101 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Recruiting | USA | ISR | GBR | ESP | BRA | 2 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06500273 | Phase II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | 0 |
NCT06508658 | Phase III | Gemcitabine + Oxaliplatin + Rituximab Epcoritamab-bysp + Lenalidomide | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | Recruiting | USA | ROU | POL | HUN | HRV | FRA | BGR | BEL | AUS | 5 |
NCT06526793 | Phase II | TNB-486 | AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Not yet recruiting | USA | ESP | DEU | CAN | BRA | AUS | 2 |
NCT06534437 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + SEL24-B489 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01) | Not yet recruiting | POL | 0 |
NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT06561425 | Phase Ib/II | GLPG5101 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (Atalanta-1) | Recruiting | USA | NLD | BEL | 0 |
NCT06594939 | Phase II | Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT06607549 | Phase I | Loncastuximab tesirine-lpyl + Rituximab | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (Lonca-R After SRS in CNSL) | Not yet recruiting | USA | 0 |